<code id='1035D033DD'></code><style id='1035D033DD'></style>
    • <acronym id='1035D033DD'></acronym>
      <center id='1035D033DD'><center id='1035D033DD'><tfoot id='1035D033DD'></tfoot></center><abbr id='1035D033DD'><dir id='1035D033DD'><tfoot id='1035D033DD'></tfoot><noframes id='1035D033DD'>

    • <optgroup id='1035D033DD'><strike id='1035D033DD'><sup id='1035D033DD'></sup></strike><code id='1035D033DD'></code></optgroup>
        1. <b id='1035D033DD'><label id='1035D033DD'><select id='1035D033DD'><dt id='1035D033DD'><span id='1035D033DD'></span></dt></select></label></b><u id='1035D033DD'></u>
          <i id='1035D033DD'><strike id='1035D033DD'><tt id='1035D033DD'><pre id='1035D033DD'></pre></tt></strike></i>

          
          WSS
          Novo Nordisk Denmark
          LISELOTTE SABROE/AFP/Getty Images

          A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

          In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

          advertisement

          Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion